EFTA00609801.pdf

BioReference LABORATORI ES en C2FeBel:Imeaks Company ORSHER, STUART - STUART ORSHER, K.D. 9 EAST 79TH ST, NEW YOR 21 Ac • P: Notes: NON FASTING EPSTEIN, JEFFREY DOB: 01/20/1953 Age: 64 V Sex: M U/FL: Bed; Rn: Patient ID: Address:0 EAST 71ST STREET, NEW YORK, Ii? 10821 FINAL REPORT Specimen ID: 104364919 Date Of Report: 09/04/2017 11:3* Date Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North Amrr-::co Ejitcrp rime: CLINICAL REPORT linital Abnormalities Eannmary (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire resift.) Glucose Cholesterol IgG BAND 41 Hemoglobin A1C CK ANA TITER (IFA) PNEUMO Ab TYPE 8 (58) PNEUMO Ab TYPE 19 (58) PNEUMO Ab TYPE 56 (58) 185 HI 226 HI Positive • 5.7 HI 346 HI 1:160 HI 0.4 LO (19F) 0.8 LO (16C) 1.3 LO LD Triglycerides HERPES I Ab.(IgG) 235 HI 1510 HI 7.40 MI HERPES II Ab.(IgG) CHLAMYDIA AB. IgG/IgM SEE BELOW • ANA SCREEN (38) PNEUMO Ab TYPE 1 PNEUMO Ab (58) (58) PNLUMO Ab TYPE 9 (9N) 0.4 LO PNEUMO Ab (58) (58) PNEUMO Ab TYPE 23 (23F) PHELPS° Ab TYPE 2E0.5 LO (58) (58) PNEUMO Ab TYPE 68 (9v) 0.4 LO B.Henselae IgG At1:64 • (58) (3) 5.70 HI Positive • TYPE 4 0.6 LO TYPE 1: Total Protein 7.3 5.9-8.4 6:4 . ITY41 edt 1.7-3.7 g/dL IA/6 Ratio . . . . 103 HI 70-99 mg/dl. :Sod' . 140 135-147 mool/L . . Potassium 4.8 3.5-5.5 mmol/L . MMol/L ii229 - —naafi .' BUN 20 8-23 creatinine • • 0.31 6:664.1e e-EFR ' 88 >or=66 mt/min fe-6FR„ -African American - ' 102 >or-60 . . ....... . mt/min . /Yea Cli - . 9.7 8.8-18.4. resjciL' 'Uric Acid : . - Iron i -Y:4 82 . • 3.4-8.5 ss.ste 66/dl vi/di friliratt-Totr e.s <1.2 . mg/dt LD 235 NI .195.225 U/L ETAiss • • '46-134 BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, NJ 07407 I James Weisberger M.D. Page 1 of 15 Laboratory Director Printed 09/08/2017 16:22 EFTA00609801 BioReference APCRAT OR . E d- OPKO Henn Company OeSHER, STUART - STUART ORSHER, M.D. 9 EAST 79TH ST, Nt..4 YO4 CLINICAL REPORT PmospHosus 'ALT_ - - MD 7 3.i <5 EPSTET4, 3EFFREY BOB: 31;2n/1153 Age: 64 r sex: M U/FL: Bee: Re: Patient ID: Addrecs: 4 PAST 71ST STREET, R.: YORK, NY 10021 P: . . 2.7-4.5 • 01. NOTE: The -esult for ALT has been confined by repeat analysis. GGTP 23 10-71 —e CARDIOVASCULAR/LIPIDS *-- Cholesterol :Trilbl!w4de NOTE: The result for Triglycerides has been confirmed by repeat analysis. CHOL., DIRECT TNP FINAL REPORT A E Specimen ID: 204304919 Date Of Report: 09/00/7017 11:30 Date Collected: 08/30/2017 11:$6 Date Received: e3/30/2017 23:12 North Patrice Eastern Ti.. U/L mg/dL — Oil U/L 226 HI 151.1—Irt >40 <200 mg/dL <150 ii7ac mg/dL Test Not Performed: Unable to perform HDL test due to elevated Triglycerides (>1290). INDL a rt:of diolesterol. TNP Y14 • Chol/HDL Ratio TNP <7.4 ilIDL/HDL' Ratio <3.56 COL'thOiesterol 'dee sox NOTE: Unable to calculate us. due to a Triglyceride level of greater than 400 mg/dL. Anic-ektillAYib . ceeCtili • 1;li" trigich: i . . • . can't Cale: one or nbre components was outside the measurable range. We are unable to calculate. I • Test Not Performed: One or more conponents were not available to perform calculation. *. 1184ATOLOGY * WBC 6.10 5.li 3.66-11.99 4:24:37017- x18(3)/uL 'AiRi5774. we ...DVS HEB 15.4 12.3-17.6 gm/di-' ' 4171 MCV 85.4 80.8.180.0 fL 29.9 NCH . ---..,....- if.0-34.1 pg 35.0 29.0-3S.O. • gill i leir7 -- ..-- ---- .. Em. POLYS 46.9 36.648.4i. t ;LYNPHS . • . 39.0 ' ---- 5411:9 :Alois . .... 7.7 . . . 0.0-13.0 S . . . Bioneference Laboratories, Inc. 401 Edward H. Ross Dr I Elmwood Park. ND 07407 I Page 2 of IS Jamesionaisberporato. Laboratory Director Printed 09/68(2617 16:22 EFTA00609802 BioReference FINAL REPORT LAB ORATOR I ES on OPKOHHamh Compeny CLINICAL REPORT EOS !ubs "fitialiet EtidateberES Platelet Count MPV I EPSTEIN, 3EFFREY • DOD' 01/20/1953 Age: 64 x Sex: M U/FL: Bed: Ra: Patient ID: egss:9 EAST 71ST STREET, NEW YORK, NY 10021 P: • • 5.4 0.2 240 9.6 Specimen ID: 104364919 Date Of Report:09/0872017 11:38 Date Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North Americo Foltern rime 0.0-8.8 0.0-2.0 > t70.4.6 isteitee xie(i)/uL 8.2-11.9 . -e -e,-.2...Z:2-Ä-z"v":-7:7.77:17.. • JRINALYSIS Co or YELLOW YELLOW, STRAW, AMBER CLEAR 1.003-1.039 5.0-8.6 NEGATIVE WOW NEGATIVE 0.2-1.0 rag/dt NEGATIVE NEGAeir NEGATIVE NEGATIVE NONE NONE 0.4 NONE-FEW 0-4 0-1 0-1 • ' NONE:FEW Character CLEAR .Specific OriVitY Or. " '1.019 Urine 6.5 Oreiern;-üani - - • ketone, Urine • NEGATIVE • ru o6ii nölten urine 0.2 ;Bilirenii, urine • NEGATIVE !elecet.urine • • • • XiüköZirli este-Ti— v e: !Crystals Urine tWine ;Epithelial Cel7.s, Br ;cast, nyeline, urine Itait; lust, ROC, urine. • . rinek-terii•; Urine - NEGATIVE NEGATIVE NEGATIVE NONE NONE 6-4 NONE SEEN NONE 8-4 NONE SEEN NONE SEEN NONE PER ter PER HPF PER LPF PER LPF • PER LPF ' I ROBIOLOGY 'CULTURE, URINE • SITE: URINE NO GROWTH NO GROWTH LyrE WS, IgG W/BANDS T--- 'IRA BAND 18 ,100 EIAND.28 rig& BAND 28 lie BAND 30 IgG BAND 39 IgG RAND 41 IgG BAND 45 rfge. BAND 58 Negative Negative wegatge 'Negative ' NegatiVe Negative Negative Negative Negative Positive • Negative Negative Negative 01oReference Laboratories, Inc. 481 Edward N. Roes Dr I Elmwood Park, N3 07407 I kDa kDa kDa kDa kDa kDa kDa kDa JamosIdNe;s6wrpor160. Rage 3 of 15 Laborstory Director printed 09/06/2017 16:22 EFTA00609803 BioReference E$ on OPKOHasith Company PSTEIN, JEFFREY FINAL REPORT ORSHER, STUART Specimen ID: 204364919 P DOB: 01/20/1953 Age: 64 V Sex: .M Date Of Report: 09/08/2017 11:30 - STUART ORSMER, M.D. A U/FL: Bed: Rm: A Date Collected: 08/36/2017 ii:se Date Received: 08/30/2017 23:12 9 EAST 79TH ST, I atient ID: NEW YORK, NY 10021 Acct k: MO E N Address:9 EAST 71ST STREET, NEW YORK, NY 10021 P: P: North Amerit0 Ehnen, Time CLINICAL REPORT IgG BAND 66 . ' NOTEt LYME ANFUMOY (Igo) by WESTERN BLOT is considered to be positive if any 5 but ofthe-following 20 bands are present: 18, 23, 28, 36, 39, 41, 45, 58, • 66, 93 k00. Nogativr Negative Negative Negative kDa ' • ' Lyme Ig6 INTERPRETATION 410 -" LYME WR, IgM W/BANDS •--- IBM BAND 23 Negative Negative lgm SAND 39 Negative Negailve IgM BAND 43. Indetermin Negative Negative Negative kDa kDa kOa NOTE: LYME ANTIBODY (18K) by WESTERN BLOT is considered to be positive if any 2 out of the following 3 bands are present: 23, 39, 41 kDa. Lyme Iglu ~IITERPNETATIOPI {d8 • Negative Negative IgE, SERUM TNP _ . . Test Not Performed: Specimen is LIPEMIC. ALLERGEN INTERPRETATION: CONCENTRATION (kUA/L) <0.10 0.10 - 0.34 0.35 • 0.69 0.70 - 3.49 3.50 - 17.49 17.30- >200.80 Hemoglobin Alt INTERPRETATION Absent Very Low LOW Moderate High Very High i HEMOGLOBIN Ale AM) eA6 REFERENCE RANGES ale(%) <5.7 5.7-6.4 v>6.5 <or=13.4.0 DIMETeS CATEGORY* Normal (non-diabetic) Increased risk of diabetes consistent with diabetes A2c(%) aNMESTIMATED AVERAGE PLASMA GL00061)(mg/dL) 6 126 7 154 8 183 9 212 10 240 11 269 22 298 aioReference Labora₹ories, Inc. 481 Edward H. Ross Dr I Elmwood Park, NJ 07407 I James Weisberger M.D. Page 4 of IS Laboratory Director Printed 09/08/2017 16:22 EFTA00609804 BioReference FINAL REPORT A & ORATOR I ES OPKOHAnIth Company ORSHER, STUART PSTEIN, 3EFFREY Specimen ID: 104364919 DOB: 01/20/1953 Age: 64 V Sex: H Date of Rdport:e9/08/201711:39 - STUART ORSHER, A /FL: Bed: it: Date Collected: 08/30/2017 11:Sa Date Received: 08/30/2017 23:12 9 EAST 79TH ST, I atient ID: NEW YORK, NY 10021 Aeet *: ".0 N Address:9 EAST 71sT STREET, KEW YORK, NV 10021 P: V: Worth 4morico EOltcrm Tlme CLINICAL REPORT *recommended ranges-American Diabetes Association(2eao) 4evia:oas NOTE: The amount of glycated hemoglobin as measured by the HbAlc test say be overestimated in African Americans and should not be used as the sole parameter of enceinte burden. Similarly, hemolysis, genetic hemoglobin variants and chemically modified hemoglobin derivatives (as seen in renal failure, smoking, aspirin use) may also affect glycated hemoglobin levels. A!0/Rh ltbf~ 'ME. .. . A Pos TNP UnwiL. . . . . . . Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. THYROXINE(TI5 rti UprAki " ?HP TNP • 4.9-12.9 ug/WL 114YROXINE, FREE VIC FREE T4 INDEX rictilffitofaluOrlIWAL !Tiiiiiiiii-(5PEP) • • - • TNP TAP • 8.80-1.73 1.5-3.8 ng/dL neal TNP :ALPHA-1-GLOB. ('SPEP) . . TNP . . TNP 8.17-6.41 6.42-6.99 0.6S-1.67 • See Graph • • sidE7 g/dL •-• i6EAGL6W.(SPE1ir'""— i4lNk4iLdi7.(s0pS;j 'REOIRE TNP • • TNP iSPEP GRATA TNP TNP ' NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RIR:OMIT a fasting specimen at your earliest convenience. I ; .. TNP 22-312 • mg/mL ' tut Noe Performed: Specimen rejected for testing due to moderate or marked • - . . • hemolysis. — • :. NEP. A Al.. TOTAL TNP • • Non-Reactive flEP-.91-S `Wriesif Nosilleactive HEP. B SURF. AB. . 71Qr ThSi Non-Reactive . . . . . . .. . Negative pip. BE AG.. — TNP Non-Reactive !Igok. SERUM 225 70-408 • Ng/di • rig% 18RSM • 1047 - - - 46 • • 40-230 mg/dL . IRPR Non- Non-Riattive Titer Reactive . . . PioReference Laboratories, Inc. 481 Edward H. ROSS DP I Elmwood Park, N3 e7407 I JamesVhdsbefgerM.D. Page 5 of 15 LmboretorfESOCIOr Printed 09/08/2017 16:22 EFTA00609805 BioReference FINAL REPORT OPICO Health Company PSTEIN, 2EFFREY DOG: 01/20/1953 Age: 64 Y Sex: m /FL: Bed: RM: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10021 T N T P: HERPES I Ab.(IgG) 7.40 NI <0.90 INTERPRETATION OF RESULTS FOR H5V-1 Antibody Index Result <0.90 AI Negative 0.90-1.89 AI Equivocal >or=1.10 AI Positive AND HSV-2 Ig6 ANTIBODY Interpretation No mSV-IgG antibody detected Equivocal result. Repeat in 4-6 weeks IRO antibody detected S A p E Specimen ID: 164364919 Date Of Report: 09/08/2017 luse Date Collected: 08/30/2817 11:58 Date Received: 08/38/2017 23:22 sionth America Eastern rue e•ocorment:This assay is type specific and will differentiate between Herpes Simplex 1 and 2 infections. Test results should be interpreted in conjunction with clinical history. The performance of this assay has not been established for pediatric populations, for neonatal screening or for testing the inaunocompromised. HERPES II Ab.(IgG) 5.7e HI 20.90 Al INTERPRETATION OF RESULTS FOR HSV-1 AND NSV-2 IgG ANTIBODY Antibody Index Result Interpretation <e.g. AI Negative No HSV-Ig6 antibody detected 0490-1.09 AI Equivocal Equivocal result. Repeat in 4.6 weeks >or-1.10 Al Positive Ig6 antibody detected **.*Conwrant:Thi•s else), is type specific and will differentiate between Herpes Simplex 1 and 2 • infections. Test results should be interpreted in conjunction with clinical histOry. ' The performance of this assay has not been established for pediatrit populations, far neonatal screening or for testing the lemunocompromised. 193.e7744.9 NOTE: Patients receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the ESA method (test code 0379-8) due to a strong interference free the drug. Clinicians are asked to request Testosterone, Total by LC/HS/NS (test code 3451-6) for these patients. I a. IN.PYLORI Ab.,Ige 0.34 346 N2 10-3es See Below WC. iN.PYLORI Ab-,IgA ...... 9.49 - wee Below H.PYLOR2 Ab.,IgM Tripird - fkal Ab. 1.44 <0.41 rEiebeSia mitratniiiIVA06) <1:20 --- - . .. anilb sinsceac iej • <1:64 <1:64 Sera frbm patients aboon to have been infected by other tick-borne , pathogens, tabeeii4uncanl, Rickettsia rickettsii and &invite burgdorfiri, were screened end found negative by the B. micron Ig6 IFA. This test was, developed and its performance characteristics determined by 1 Viracor:Eurefins. It has not been cleared or approved by the U.S. FOX and - DrugAMOniitretion. Tosting!PerfOrmed At: Viracor Sureties' _ . BloReforence Laboratories, Inc, 481 Edward H. Ross Or I Elphood Park, a7 07407 James Welsberger M.O. Page 6 of 15 Laboratory Director Printed 09/98/2017 16:22 EFTA00609806 BioReference I 4908470R I CS on OPKO Health Conwieny ORSHER, STUART - STUART ORSHER, M.D. 9 EAST 79TM ST, NEW YORK, NY 10021 Acct 4: NO CLINICAL REPORT 1001 NW Technology Drx e Lee's Stmuit, MO 64086 Tetanus Antibody IgG (SO) . . IIIII--- EPSTEIN, 3EFFREY DOB: 01/20/1953 Age: 64 V Sex: m U/FL: Bed: Rm: Patient ID: AddreSS:a EAST 71ST STREET, NEW YORK, NY 10021 P: 1.37 >0.1 "This test was developed and its performance characteristics determined by Viracor Eurofins. It has not been cleared or approved by the O.S. Food and • Drug Administration. ' Testing Performed At: Viracor Eurofins 1001 NW Technology Drive 64006 ULAN 60- 3 0.31 r >0.1 Testing Performed At: Viracor Eurofins 2001 NW Technology Drive Lee's Summit MO 64086 MA ”k il.4 . 983643 'HD/ Ag/Ab TNO Non-Reactive Test Not Performed: Unable to perform HIV testing, specimen is LIPEMIC. • Assay Information: Assay for the detection of HIV p24 antigen and antibodies to Human Deminodeficiency Virus Type i,including Group 0 (HIV-1 + "0") and/or Type 2 (HIV-2) Method: Chemiluminescence (Siemens Healthcare Diagnostics) CMIANYDIKAN:116itin. tier SEE BELOW • C. pneumonia, IgM Titer <1:20 <1:20 C. track 1g21 Titer <1:20 <1:20 C. psittaci IgM Titer <1:20 <1:20 C. pneumoriae Iv Titer 1:121 H <1164 E. tract' IgG Titer el:64 <1:64 C. psittaci IgG Titer <1:64 <1:64 • -INTERPRETIVE INFORMATION: C. psittaci IgG Titer --The chiamydia antibody test contains both species- and genus - --specific antigens, and strategical cross-reactions may be seen in sioReference Laboratories, Inc. 411 Edward H. Ross Or I Elmwood Park, NJ 07407 FINAL REPORT IUML specimen ID: 104364919 Date Of Report: 00/0S/2912 11:30 Date collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 NOrth Amcrica Eastern Tiett James Wriobercier M.D. Page 7 of 15 Laboratory Director printed 09/08/2027 16:22 1 EFTA00609807 BioReference FINAL REPORT ASC .T ATPR I ES nn OPKO Mnnhth Company ORSHER, STUART - STUART ORSHER, M.O. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct m: P: EPSTEIN, JEFFREY DOB: 81/20/1953 Age: 64 y Sax: m U/FL: Bed: Rm: Patient ID: ress:9 EAST 71ST Meat, NEW YORK, Ny 10021 oth acute and conva escent samp es (less t an 1:128 . A C. --pneomonlae-specific reaction will exhibit titers twofold or --greater than titers observed with the C. trachomatis or C. • --psittaci serology. Any IgG titer may indicate past exposure to --that particular species. IgG titers in recently infected --indiyiduals are typically grater than or equal 1:512. --The Chlamydia microimminofluOrescent assay slides utilize C. --psittaci, C. pOtymoniae, and nine serotypes of C. trachomatis. The --LGV strains of C. trachtmatis are not included in this assay. --Test developed and characteristics determined by OUP --Laboratories. See Compliance Statement 4: aruplab.com/CS --www.aruplab,com, Julio Delgado, MD - Lab. Director QUINTANA Affdik (30) SEE BELOW B. quintana Ab, IgM < 1:16 --INTERPRETIVE INFORMATION: Bartonella quintana Ab, Ism -- Less than 1:16 Negative-No significant level of Bartonella quintana IgM antibody -- detected. -- 1:16 or greater Positive-Presence of IgM antibody -- to Bartonella quintana detected, -- suggestive of current or recent -- infection. --The presence of Igm antibodies suggests recent infection. Low --levels of IgM antibodies may occasionally persist for more than 12 --months post-infection. --Test developed and characteristics determined by AAUP --Laboratories. See Compliance statement A: aruplab.com/cS --mvw.aroPlab.com, Julio Delgado, MD - Lab. Director B. quintana Ab, IgG <1:64 --INTERPRETIVE INFORMATION: Bartonella quintana Antibody, IgG -- Less than 1:64 Negative: No significant level of Bartonella quintana IgG antibody detected. 1:64 - 1:128 Equivocal: Questionable Presence of Bartonella quintana IgG antibody detected. Repeat testing in 10-14 days may be helpful. 1:256 or greater Positive: Presence of IgG antibody to Bartonella quintana detected, suggestive of current or past infection. --A low positive suggests past exposure or infection, while high --positive results may indicate recent or current infection, but is --inconclusive for diagnosis. Serocorversion between acute and BioReference Laboratories, Inc. 481 Edward H. Ross Or I !Inwood Park, N3 07407 I Specimen ID: 104364929 Date Of Report: 09/00/2017 11:30 Date Collected: 08/30/2017 11:Sa Date Received: a8/30/2017 23:12 north Asorft0 &deem rtot JarnmeMftnabersperlAIL Page 8 Of 15 LaboratoryDbettor printed 09/08/2017 16:22 EFTA00609808 (58) . Performed by: BioReference _AscRATOR I Es an OPKO Hent Comonny ORSHER, STUART - STUART ORSHER, M.D. 9 EAST 79TH ST, NEw YO 21 acct 4: P: CLINICAL REPORT --convalescent sera is cons ered strong evidence of recent --infection. The best evidence for infection is a significant change --on two appropriately timed specimens where both tests are done in -.the same laboratory at the same time. --Test developed and characteristics determined by ARUP --Laboratories. See Compliance Statement A: aruplab.con/CS EPSTEIN, 3EFFREY DOS: 01/29/1953 Age: 64 Y Sex: M U/FL: Bed: Rs: Patient ID: Address:9 EAST 71ST STREET, New YORK, NY 10021 C • TWO Non-Reactive Test Not Performed: ile were unable to perform the Hepatitis test(s) requested due to lipimia. Please resubmit a fasting specimen. NEP C Ab. (S/CO RATIO) (30) Performed by: MOP 500 Chipeta Way Salt Lake City, UT 84108 viracor Eurofins Clinical Diagnostic 1001 NW Technology Drive Lees Summit, MO 66086 PIP <0.80 . Test Not Performed: One or more components were not available to perform calculation. H.PYLORI (IgG, IgA, IgM) REFERENCE RANGES RESULT (UNITS) INTERPRETATION <0.89 NEGATIVE 0.89.0.99 EQUIVOCAL >0.99 POSITIVE NOTE: This is a screening test for H.PYLORI. The diagnosis of gastritis and peptic ulcers should be assessed with the patients medical history and clinical symptoms. Results in the equivocal range should be rechecked with a now specimen in 2.5 weeks. NOTE: The H. Pylori, IgM test was developed and its performance characteristics were determined by Biogeference Laboratories. It has not been cleared by the U.S. rood and Drug Adminis- tration. the FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test. ASSAY INFORMATION: Method ELM NOTE: A result of equivocal or positive for B.burgdorferi (Lyme Ab) should not be interpreted without supplemental western Blot testing. "Lyme Antibody ranges (IgG/IgM)*. <0.91 . Negative 0.91-1.09 = Equivocal lioReference Laboratories. Inc. 481 Edward H. Ross Dr I Elmwood Park. N3 07407 I FINAL REPORT imen ID: 104364919 to Of Report: 09/08/2017 11:30 Date collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North America Eastern Vise JanwmcNielsbergerNUD. Page 9 of 15 Laboratoryterector Printed 09/08/2017 16:22 EFTA00609809 BioReference FINAL REPORT a scRA - ) R . ES OFIKO Heal: Cornoany ORSHER, STUART - STUART ORSHER, M.D 9 EAST 79TH ST, NEW YORK, NY 10021 ACC: n: p. Marker Vice. -1 EPSTEIN, 7EFFREY DOS: 02/2e/1953 Age: 64 y Sex: m U/FL: Bed: km: Patient ID: Address:9 EAST 71ST STREET, MO NEW YORK, NY 10021 P: >1.09 = Positive Hepatitis 8 Result Interpretation (for reference use only) LX/EA• Acute Past Chronic HBV ib3sAg HBeAg HEP.R.CORE Agar HEP.B.CORE AB. H8eAb HBsAb m/- 'Late Incubation/Early Acute NOTE: In remote past infection, HBsAb level may be Negative or Non-Reactive in sore patients. +/- AikBdOEEN Positive • Neg,<1:80 !dip ' - 0.2 <0.5 ,ESR (Std,-Rate,' 15 <21 FeCiC '' Ado TNP >5.38 __ .. mg/dL an/hr ng/mL . . Specimen ID: 104364919 Date Of Report:09/08/2017 11:30 Date Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North America Eastern Time Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. Folic Acid Range Normal Borderline deficient Deficient Excessive units (ng/.L) >5.38 3.38-3.3S 0.35-3.37 >24.00 iii-912 pgJEL . . . ! Test Nat PerfOrBed! Specimen rejected for testing due to moderate or marked .p hemolysis. 250X, VITAMIN D TNP Test Not Performed: unable to perform testing, specimen is ilagNIC. VITAMIN 0,25-OH TEST INFORMATION Range (ng/mL) <20.0 20.0-31.9 32.0.100.0 )109.0 ,747 171;WOHYDROBY TNP . Test Not Performed: Unable to perform testing, specimen is LIPEMIC. BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N7 07407 I Suggested Interpretation Deficient Insufficient Sufficient Possible Adverse Effects 29.9-79.3 pgfial JammsWeisbergmrk10. Page 10 of 15 LabormoryDirector Printed 09/88/2017 16:22 EFTA00609810 Bio Reference FINAL REPORT - A 9 09ATOR i ts en C7SaPCC3 Health Ccrnpnny MiNER, STUART - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK NY 10021 ACCt *: P: ND mUMPS VIRUS Ab.(igG) 3.07 IICOOTTerICD1 IIIII EPSTEIN, JEFFREY DOS: 01/20/1953 Age:64y Sex: M U/FL: Bed: Rm: Patient ID: AddresS:D EAST 71ST STRICT, NEW YORK, NY 16021 P: Immunem>1.09 Specimen ID: 104364919 Date or Report: 09/88/2017 11:Je Date Collected: e8/30/2017 11:58 Date Received: 08/30/2017 23:12 North Americo Eastern Time RANGES FOR LEAD, BLOOD Reference Range (ug/dL) Adult/Child <5.0 Occupational <40.0 NOTE: Lead risk guidelines conform to CDC Guidelines. BioReference is an OSHA-APPROVED lab for lead testing. NOTE: Blood lead levels in the range 5.0-9.9 ug/dL have been associated with adverse health effects in children aged 6 years and younger. NOTE: All Lead results m/>5.0 ug/dL are confirmed by repeat analysis. NOTE: Capillary and microtainer blood levels =/>5.0 ug/dL may be due to contamination from lead found on the finger surface and requires confirmation on venous blood. NOTE: This test for LEAD was developed and its performance characteristics were determined by BloReference Laboratories. It has not been cleared by the U.S. Food and Drug Administration. TM FDA has determined that such clearance or approval is not necessary. This test Is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test. ASSAY INFORMATION: ICP-MS Immunotyping, Serum IMP Negative NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RESUBMIT a fasting specimen at your earliest convenience. AERainii; BLOOD (30) 6-le ug/L INTERPRETIVE INFORMATION: Mercury, Blood Blood mercury levels predominantly reflect recent exposure and are most useful in the diagnosis of acute poisoning as blood mercury concentrations rise sharply and fall quickly over several days after ingestion. Blood concentrations in unexposed individuals rarely exceed 20 ug/L. The provided reference interval relates to inorganic mercury concentrations. Dietary and non-occupational exposure to organic mercury fonts may contribute to an elevated total mercury result. Clinical presentation after toxic exposure to organic mercury say include dysarthria, ataxia and constricted vision fields with mercury blood concentrations from 20 to 50 ug/L. Test developed and characteristics determined by ARUP Laboratories. 5te Compliance Statement aruplab.Com/CS www.aruplab.00M, Julio Delgado, MD - Lab. Director RUBEOLA/MEASLES(IgG) 1.81 Immunem>1.09 BioReftrence Laboratories, Inc. 481 Eduard H. Ross Dr I Elmwood Park, NJ 07407 I James Welsbner M.D. Page 21 of 15 Laboratory Director printed 09/03/2017 16:22 EFTA00609811 BioReference FINAL REPORT IMPKO vff t• .••• . 0 C 0 RSHER, STUART - STUART ORSHER, MAL EAST 79TH ST, NEW YORK N. Acct 4: P4 CLINICAL REPORT VARICELLA ZOSTER,Ig ND . . . . EPSTEIN, JEFFREY DOB: 82/20/1953 Age: 64 V Sex: M U/FL: Bed: Rm: Patient ID: AddneSS: 9 EAST 71ST STREET, .VW YORK, NY 10821 P: REFERENCE RANGE for Varicella.zoster Ip1 Abs: Less than 0,91 Negative 0.91 - 1.09 Equivocal Greater than 1.09 Positive Results from any one IgN assay should not be used as a sole determinant of a current or recent infection. Because an IgM test can yield false positive results and low levels of IgN antibody may persist for more than 12 months post infection, reliance on a single test result could be misleading. Acute infection is best diagnosed by demonstrating the conversion of IgG from negative to positive. If an acute infection is suspected, consider obtaining a new'specimen and submit for both IgG and IgM testing in two or more weeks. .VARICELLA EOS.(IgG) 3.46 Immune=>1.09 INP 13.0-85.0 Dg/ml Test Not Performed: Specinen rejected for testing due to moderate or marked hemolysis. .RHEUMATOID 04 TITER <le iONDELLAAG . TNP Test WIdt Performed: Specimeisrefected for testing due • hemOlyils. . . . liTSFISTATEN OF RESULTS FOR RUBELLA 10 ANTIBODY I . *mita IZU/mL) Interpretation 4.9.0 Negative Non-Immune 5;0 r 9.9 Equivocal Retest > 9;0 Positive Immune interpreted as EQUIVOCAL indicate a level of antibody below the -Positive.(Immune) cut off. Repeat testing on a neW specimen is Suggistbd tv assess antibody response after a booster shot or a viral Syndrome... • ASSAYINRINgilblit ;Hotbed Chemilumipescence (Siemens Diagnostics) :ANA TITER (IFA) 1:160 III 0.:00 ANA PATTERN = HOMOGENEOUS MD SPECKLED <IA Wet Immurtes>9.9. 1117iL to moderate or marked Titer Specimen ID: 104364919 Date Of Report: 09/80/2017 11:30 Date Collected:OE/30/2017 11:53 Date Received: 00/3e/2017 23:12 North America Eastern Time J Antibodies To Association Frequency ate Screening test for SLI In symptomatic patients. (Antinuclear Ab, 95.100% BioReference Laboratories, Inc. JarnesVeniabergerMn. Page 12 of 15 Ass Edward H. Ross Dr I Elmwood Park, N1 07407 I Laboratory Director Printed 09/08/2017 16:22 EFTA00609812 Bio Reference FINAL REPORT LAIORATOR IES en CiPNCCRrieafth Compeny ORSHER, STUART - STUART ORSHER, M.O. 9 EAST 79TH ST, NEW YORK NY 1.0021 Acet 9: MO P: CLINICAL REPORT re assay ANA ANA ANA IIIII EPSTEIN, 7EFFREY DOB: 01/20/1953 Age: 64 Y Sex: M U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEN YORK, m' 10021 P: Assist with diagnosis of Scleroderna (Systemic Sclerosis). Sjogren's Syndrome. Idiopathic Inflammatory Polymyositis or Dereatemyositis• IIIII Specimen ID: 104364919 Date Of Report: 09/08/2017 11:30 Date Collected:08/30/2817 11:58 Date Received: 08/30/2017 23:12 North America fasten, rime 60-S0% 40-78% 38.80% Antibodies to specific (Extractable) Nuclear Antigens (ENA)/Proteins dsONA Sm(Smith) SS A (Ro) 55 8 (La) 55 B (La) scl-70 7o-1 Centromere U1 nRNP Nistone Proteins Characteristic of SLE. Rare in other CTDs. Highly associated with active disease. Highly specific for SLE. Uncommon in other diseases. Associated with SLE, Neonatal Lupus and 5jogren's Syndrome. Associated with SLE. Associated with Sjogren's Syndrome. (anti DNA Topoisomerase) Associated with Diffuse Scleroderma and rarely co exists with anti-Centrowere Abs which are associated with Limited SchrOderme Disease. Associated with Polymyositis or Dermatomyositis. Identified by staining pattern. Their presence is associated with CREST Syndrome (Limited Systemic Sclerosis). Used to categorize Mixed Connective Tissue Disease (MCTD). (Chromatin) Associated with drug induced LE. 25-85% 15-301 35-60% 15% 44-6(ed 34-40% 28-25% 88% High Correlation 90.100% . ref:Krranaugh,A(et al.):Guldelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens. Arch.Pathol Lab Med. Vol.124,2an 2000. PPIEUND 91 Y.V931"(39) <0.3 Lii >1.3 PNEUMO Ab fliiii.i -liii ' - -- 1.4 ' - - '›i'i. ' --.. '' .ugiii. -.- PNEUMO Ab TYPE 4 (ill— • LE LO itli — ugniL PNEUMO Ab TYPE 8 (58) 0.4 10. >1.3 ugint . . . . . . . PNELNO Ab TYPE 9 UN(F (58) 0.4 LO >1.3 ONEUMO Ab TYPE 12 (120 (58).. .. '' 40.0 0 >1.3 '' '' PHEW Ab ISIPE.I.M5g5 23.2 >1.3 ONEU710 Milti91-13. tisirj• (58) . • • • 0.8 Lo >I:3 • - - • T.91.rio:Th'itiirbTarr (91) 49.3 LA 31:1- 1PALuno Ab TYPEidiSei) (Sii - • - .. i3:5. LO >1;3. - - Pmatimark 'TYPE 5 (58) 7.8 >1.3 . . . .. - ugh& ughst ug/iL ug2ML ioNEUMD- Ab TYPE 51 (7P) (58) 1.5 >1.3 ug/n1 - - wasp Ab TYPE sutrienisT _ :_".......irw .r" 4 . . "51.7C =..... . " iiigir 7 .. 7 U. .... :PNEUMO Ab TYPE 68 (9V) (58) 0.4 LO >1.3 ug/mL Testing Performed At: ' Viracor Eurofins 1001 NW Technology Drive " 64386 LLc - . 43 .Atistilit,"315393" BioR eeeeeeee Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park. 87407 ug/L 1 . T James Weisberger M.D. Page 13 of is Laboratory Director printed 00/08/2017 16:22 . • • • EFTA00609813 BioReference FINAL REPORT LABORATOR ES an ['PAC(' Health Company ORSHER, STUART C3070 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct 0: CLINICAL REPORT A.Phagocytophila LEG Ab (24) <1:64 8.Henselae IgG Ab (3) 1:64 * < 1:64 titer B.Henvelae ICI Ab (3) <1:20 < 1:20 titer EPSTEIN, JEFFREY DOB: 01/20/1953 Age: 64 Y Sex: M U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEw YORK, NY 20021 This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Interpretation (24) SEE NOTE ANTIBODY NOT DETECTED REFERENCE RANGE IgG <1:64 IgM <1:20 Anaplasna phagocytophilum is the tick-borne agent causing Human Granulocytic Ehrlichiosis (HGE). HGE Is distinct and separate from Hunan Monocytic Ehrlichiosis (HMI), caused by Ehrlichia chaffeensis. Serologic crossreactivity between A. phagocytophilue and E. chaffeensis is minimal (5-15%). This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by the U.S- Food and Drug Administration. The FDA has determined that such clearance or approval is not ' necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Quest Infectious Disease 336498 Ortega Hwy (3) Performed by: (24) Performed by: Quest Diagnostics Nichols Institute of Valencia 27027 Tourney Road Valencia, CA 91355-5306 Quest Infectious Disease 33608 Ortega Highway San Juan Capistrano, CA 92675 "medical Director Hollis J. Batterman, MD (30) Performed by: AMP 580 Chipeta Way Salt Lake City, UT 84108 (58) Performed by: Viracor EuroFins Clinical Diagnostic BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park. ft 07407 Specimen ID: 104364919 Date Of Report: 09/08/2017 11:S0 Date Collected: 08/30/2017 11:58 Date Received: 00/30/2017 23:12 North AmartCO Eastern Timis ... •••••••••••••••• JmnesehAsbereirat0. Page 14 of 15 Lebonmorypeechw Printed 09/08/2017 16:22 EFTA00609814 BioReference LABOtarpR I ES mr OPKO Hawn Cempony ORSHER, STUART - STUART ORSHER, H.D. 9 EAST 79TH ST, NEW YORK, NY 1:3021 Acct ♦; P: MD 1001 im Technology Drive Lees Summit, MO 66086 INTERPRETATION OF RESULTS FOR RUOEOLA(MEASLES),MUMPS,VARICELLA VIRUS ABS. Interpretation EPSTEIN, SEFFREY DOB: 01/20/1953 Age: 64 V Sex: N U/FL: Bed: Rm: Patient /0: dreSS:9 EAST 71ST STREET, NEW YORK, NY 10021 P: Range < or . 0.90 Negative Non-Immune 0.91 - 1.09 Equivocal Retest > or 1.18 Positive Immune Results interpreted as EQUIVOCAL indicate a level of antibody below the positive (Immune) cut off. Repeat testing on a new specimen is suggested to assess antibody response after a booster shot or a viral syndrome. I NOTE: The following tests: SERUM SELENIUM, SERUM CHROMIUM, ARSENIC BLOOD and CADMIUM BLOOD were developed and their performance characteristics were determined by BioReference Laboratories. They have not been cleared by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform these tests. NOTE: The specimen submitted was MARKEDLY hemoly2ed. Some results may be affected. Please resubmit as needed. NOTE: Specimen submitted is L/PEM1C. This may cause inaccurate results. Please resubmit a fasting specimen at your earliest convenience. 82oReferonco Laboratories, Inc. 601 Edward H. Ross Dr I Elmwood Park, NS 07487 I FINAL REPORT cimen ID: 184364919 Date Of Report: 09/00/2017 12:38 Date Collected: 08/30/2017 12:58 Date Received: 08/30/2617 23:12 North America Eastern Time JernesweiabergeflA.D. Page 15 of 15 LaboudoniCHreeter printed 89/08/2017 16:22 EFTA00609815